February NCI Office of Advocacy Relations Update

National Cancer Institute sent this bulletin at 02/05/2019 03:54 PM EST
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

 

 

You are subscribed to the Office of Advocacy Relations Update from the National Cancer Institute. Read highlights of the latest news and upcoming events happening at NCI. 

 

Upcoming Events

“Genomics: How DNA Can Inform Cancer Diagnosis and Treatment” NCI Facebook Live February 7, 2019, 3-4 P.M. ET

National Cancer Advisory Board (NCAB) Meeting, February 12, 2019

Frederick National Laboratory Advisory Committee (FNLAC) Meeting, February 20, 2019

Clinical Trials and Translational Research Advisory Committee (CTAC) Meeting, March 6, 2019

NCI-MATCH Trial Update Webinar, March 6, 2019, 4:30-5:30 P.M. ET (WebEx link to be sent at a later date)

 

Note: Videocasts for advisory board meetings will be available at https://videocast.nih.gov/ the day of the meeting and will be archived shortly after for viewing on demand.

Upcoming NCI Director Appearances

  

Dr. Sharpless will be speaking at the following in February:

 
Massachusetts General Hospital, February 6-7, 2019, (Boston, MA)

H. Lee Moffitt Cancer Center & Research Institute, February 26, 2019, (Tampa, FL)

 

For ongoing updates, follow @NCIDirector on Twitter.

Recent NCI Announcements

  

Lung-MAP Precision Medicine Trial Expands To Include More Patients (January 29, 2019)

The Lung Cancer Master Protocol (Lung-MAP), the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI) is undergoing a major expansion to include patients with all non-small cell lung cancers.

 

JAMA Viewpoint: Modernizing Clinical Trials for Patients With Cancer (January 23, 2019)

This JAMA Viewpoint co-authored by NCI Director Dr. Ned Sharpless and NCI DCTD Director Dr. James Doroshow shares NCI’s vision for modernizing clinical trials.

 

AI approach outperformed human experts in identifying cervical precancer (January 10, 2019)

A research team from NIH and Global Good has developed a computer algorithm that can analyze digital images of the cervix and identify precancerous changes that require medical attention. The AI approach could be valuable in low-resource settings.

 

BRCA Exchange aggregates data on thousands of BRCA variants to inform understanding of cancer risk (January 9, 2019)

The BRCA Exchange, a global resource that includes data on thousands of inherited variants in the BRCA1/BRCA2 genes, is available to the public through a website and new smartphone app.

Recent Cancer Currents Posts

  

Glioblastoma Study Highlights Sex Differences in Brain Cancer (January 30, 2019)

Men and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.

 

African American Men More Likely to Die from Low-Grade Prostate Cancer (January 28, 2019)

For African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the increase, the risk is still small.

 

Managing Cancer Pain: Are Better Approaches on the Horizon? (January 23, 2019)

Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.

 

Immunotherapy Effective in Alveolar Soft Part Sarcoma (January 9, 2019)

People with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.

 

Atezolizumab Approved for Initial Treatment of Metastatic Lung (January 7, 2019)

On December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.

 

Read more news at the Cancer Currents blog.